Subscribe to Money Morning get daily headlines subscribe now! Money Morning Private Briefing today's private briefing

Cyclacel Pharmaceuti (NASDAQ: CYCC)

$3.65 USD $0.23 (6.73%)
Last Price $3.65
Net Change $0.23 (6.73%)
Bid $3.62
Ask Price $3.65
Open Price $3.45
Previous Close Price $3.42
High Price $3.66
Low Price $3.45
Number of Trades 195
Volume 60,472
Fifty Two Week High $9.72 (2016-08-22)
Fifty Two Week Low $3.05 (2016-11-08)
Average Daily Volume 88,865
Share Outstanding 4,250 Shares
Total Dividend Payout 0.15/yr
Dividend Yield 4.72%
1st Quarter Earnings $ ()
2nd Quarter Earnings $ ()
3nd Quarter Earnings $ ()
4th Quarter Earnings $ ()
PE Ratio $0
EPS Growth $38.19
Recent Earnings $
Annual EPS $-5.35
Last Quarter EPS $
Market Capitalization $0.02B
Insider Shareholders % 0.04%
Annual Revenue $0B
No. Shares Outstanding 4,250
Inst. Shareholder % 16.29%
Annual Net Income $0B
TTM Net Profit Margin $100.1
1-Year Return -28.47%
3-Year Return -91.66%
5-Year Return -93.55%
5-Year Revenue Growth 0%
5-Year Earnings Growth 0%
5-Year Dividend Growth 0%
Annual Dividend $0
Annual Dividend Yield 4.72%
Change in EPS YTD 38.189999%
Dividends per Share $0.15
Stock Split Ratio 1-12
Beta 3.01
CYCLACEL is a biopharmaceutical company dedicated to the discovery development and commercialization of novel mechanism-targeted drugs to treat human cancers and other serious disorders. Three orally-available Cyclacel drugs are in clinical development. Sapacitabine a cell cycle modulating nucleoside analog is in Phase 2 studies for the treatment of acute myeloid leukemia in the elderly myelodysplastic syndromes and cutaneous T-cell lymphoma. Seliciclib (CYC202 or R-roscovitine) a CDK inhibitor is in Phase 2 for the treatment of lung cancer and nasopharyngeal cancer.

CYCC News & Stock Updates